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 ABSTRACT 
 
Circulating lipoproteins are increasingly recognized as innate immune effector 
molecules. Severe hypolipidemia, which may occur with trauma or critical illness, is 
clinically associated with bacterial pneumonia. Importantly, pneumonia caused by 
Staphylococcus aureus is a major cause of morbidity and mortality in both hospital- and 
community-acquired pneumonia cases. Here we report that lipoprotein deficiency impairs 
early pulmonary innate defense against S. aureus quorum-sensing dependent 
pathogenesis. Specifically, apoB levels in the lung early post-infection are significantly 
reduced with lipoprotein deficiency, coinciding with impaired host control of S. aureus 
agr-signaling and increased agr-dependent morbidity and inflammation. Given that 
lipoproteins also inhibit LTA- and LPS-mediated inflammation, these results suggest that 
hypolipidemia may broadly impact post-trauma pneumonia susceptibility to both Gram 
positive and Gram negative pathogens. Together with previous reports demonstrating that 
hyperlipidemia also impairs lung innate defense, these results suggest that maintenance of 
normal serum lipoprotein levels is necessary for optimal host innate defense in the lung.  
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Chapter 1 – Introduction 
 
Methicillin-resistant Staphylococcus aureus 
 
S. aureus is a Gram-positive bacteria and a human commensal of the skin and the 
anterior nares of the upper respiratory tract, with ~20% of the world’s population being 
persistently colonized, and an additional ~60% being transiently colonized [1]. The 
measure of S. aureus as a successful commensal is clearly indicated by its ubiquitous 
prevalence among the human population. In addition, S. aureus is also one of the most 
important bacterial pathogens world-wide, based on its prevalence in hospital and 
community acquired infections [2-4], and the particular virulence of more recent 
emerging antibiotic resistant strains. Since the 1990s, highly virulent community acquired 
methicillin-resistant S. aureus (CA-MRSA) strains have become more prevalent world-
wide, leading to significantly increased lengths of hospitalization and healthcare costs [5, 
6], though the mechanistic reasons for increased virulence in CA-MRSA strains is still 
incompletely understood [6]. Importantly, in 2013 MRSA was identified as a “serious 
threat” organism by the U.S. Centers for Disease Control (CDC), and was the direct 
cause over 11,000 deaths in 2011 [7]. However, this is likely an underestimation of the 
true mortality costs of MRSA as cases in which it contributed to death were not included 
in this study. 
 
 
2 
 
MRSA Pneumonia 
 
While S. aureus is a leading cause of skin and skin structure infections (SSSI), it 
can also lead to more severe life-threatening illnesses, such as bacteremia, endocarditis, 
and pneumonia. Pneumonia caused by S. aureus is a major cause of morbidity and 
mortality, particularly in cases of post-influenza pneumonia [2]. With the rise in MRSA 
cases over the past two decades, along with increases in prolonged ventilator support in 
an aging and chronically ill populations, there has been a significant increase in the 
number of hospital-acquired pneumonia and ventilator-associated pneumonia cases, with 
MRSA accounting for 20-40% of these [4]. A survey of 59 US hospitals in 2005 revealed 
that MRSA accounted for a significant portion of community and hospital acquired 
pneumonia cases, as well as a significant portion of healthcare and ventilator-associated 
pneumonia cases, with S. aureus being the only pathogen independently associated with 
mortality [3]. With the rise in pneumonia caused by MRSA, There is a need for an 
enhanced understanding of specific host-pathogen interactions during S. aureus infection 
in the lung. 
 
The accessory gene regulator, virulence, and pneumonia 
 
The dichotomy of S. aureus as a ubiquitous commensal and a highly virulent 
pathogen is, in part, regulated by the accessory gene regulator (agr) operon. The agr 
operon encodes a two-component, secretion controlled quorum-sensing (QS) system that 
mediates a temporal and cell-density-dependent “switch” from a colonizing to an 
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invasive and virulent phenotype [8] (Figure 1.1). This conserved four gene operon 
consists of agrA-D, which is expressed from the P2 promoter [9]. AgrD is a linear peptide 
that is cyclized into a mature auto inducing peptide (AIP), and secreted through the 
transmembrane protein, AgrB. Secreted AIP signals in an autocrine and paracrine manner 
through the transmembrane histidine kinase receptor, AgrC, causing autophosphorylation 
of this receptor. AgrC, in turn, phosphorylates the transcription factor AgrA, allowing 
AgrA to activate the P2 and P3 promoters. Activation of the P2 promoter drives 
expression of the four gene operon, creating a positive feedback loop by increasing agr 
gene transcription. AgrA activation of transcription from the divergent P3 promoter 
drives expression of RNAIII. RNAIII is a small effector RNA which modulates 
expression of hundreds of genes, and turns on an arsenal of virulence factors including a 
number of hemolytic toxins, lipases, proteases, and many other exotoxins necessary for S. 
aureus invasive infection [8, 10]. 
Among the most studied agr-regulated virulence factors shown to play a role in 
the pathogenesis of S. aureus pneumonia are alpha-hemolysin (Hla), Panton-Valentine 
leukocidin (PVL), and the phenol soluble modulins (PSM). Hla is a hemolytic toxin 
which is post-transcriptionally regulated by RNAIII [11], and has been shown to be an 
important contributor to pathogenesis of S. aureus pneumonia [12, 13]. Through 
interaction with the mammalian cell surface receptor ADAM10 [14, 15], Hla forms a 
heptameric, barrel shaped, cytolytic pore. This in turn causes a loss of cell membrane 
integrity due to potassium efflux, activating the NLRP3 inflammasome, and eventually 
leading to cell death [16-18]. PVL is a β-barrel pore forming toxin which is cytotoxic to  
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Figure 1.1 - The S. aureus accessory gene regulator (agr).  
The agr operon mediates a density dependent phenotype switch from colonizing to 
invasive via a positive feedback loop. This in turn increases production of the global 
effector RNA, RNAIII, which regulates the expression of an arsenal of virulence factors. 
[8]. 
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leukocytes [19]. Although, PVL has been epidemiologically associated with CA-MRSA 
infection world-wide [20], its contribution to invasive disease, specifically necrotizing 
pneumonia, has been controversial [20-24]. PSMs are small amphipathic lytic peptides 
considered major virulence determinants associated with leukocyte destruction [25], and 
whose expression modulates Hla expression [26]. PSMs have been shown to be important 
for biofilm structuring and dispersal [27]. Introduction of the PSM expressing locus, psm-
mec, into non-PSM expressing S. aureus strains promoted biofilm formation [28]. 
Together, these studies suggest that PSMs may contribute to biofilm infections such as 
those associated with catheters and ventilators. Together, these agr-regulated virulence 
factors which play a role in S. aureus pneumonia pathogenesis highlight the importance 
of understanding host innate immune responses in the lung which target this QS system. 
  
Innate immunity in the lung 
 
The human lung is the largest air to surface exposure site in the human body, with 
millions of liters of air ventilated throughout the human lifespan [29], and is thus 
constantly exposed to an array of foreign particles and airborne microbial organisms 
(Figure 1.2). To avoid constant infection, innate immunity in the lung has become highly 
adapted, using physical and chemical barriers in the form of surfactant, the mucocilliary 
escalator, antimicrobial peptides (AMP), and lung-specific immune cells. 
The lung expresses many AMPs, including lysozyme, α-defensin and β-defensin, 
lactoferrin, surfactant proteins A and D, and cathelicidin. As part of the first-line of 
defense, AMPs help to directly prevent infection and limit subsequent, potentially
6 
 
 
Figure 1.2 - Innate immunity in the lung.  
(1) The lung uses a mucocilliary escalator as a physical barrier that continuously removes 
foreign particulates, including potentially harmful microbes. (2) Additionally, lung 
epithelial and resident immune cells secrete a myriad of antimicrobial peptides that act to 
limit the viability and infectivity of invading pathogens. (3) Resident immune cells 
function to phagocytose and remove invading pathogens, and in the case of more severe 
infection, regulate inflammation to limit pathology from recruited neutrophils. 
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damaging inflammatory responses [30]. However, these AMPs can also have direct 
effects on host cell immune cell function. Antimicrobial lung surfactant proteins have 
been shown to directly act on lung resident alveolar macrophages (AM) in both a pro- 
and anti-inflammatory manner, dependent on the lung microenvironment [31]. For 
example, SP-A has also been shown to induce respiratory burst and nitric oxide synthase 
(NOS) expression in AMs [32]. Invading pathogens first interact with alveolar epithelial 
cells and AMs, which in turn secrete chemokines including IL-8 and RANTES, to recruit 
inflammatory cells such as neutrophils, monocytes, and Natural Killer (NK) cells [33-35]. 
The resident proximity of AMs to the alveolar epithelium and lumen makes them well 
suited for lower airway innate immune defense [36]. AMs have been shown to be 
essential for phagocytic clearance of a multitude of airway infecting microbes [37, 38], 
and the phagocytic abilities of AMs is enhanced during infection and inflammation in the 
lung [39]. In addition to their role in removing invading pathogens, AMs and lung 
resident dendritic cells, along with regulatory T cells and the lung epithelium, regulate 
and minimize potentially damaging inflammation caused by neutrophils [29], via 
production of anti-inflammatory cytokines such as IL-10 and TGF-β [40].  
While neutrophils are critical to host defense against invading pathogens in the 
airway [41, 42], they are also involved in inflammatory pathology in various disease 
states [42, 43]. The local inflammatory response during lower airway bacterial infection 
is a complex and important process, necessary for host immune defense in the lung 
(Figure 1.2). Toll-like receptors (TLR) on neutrophils recognize specific pathogen-
associated molecular patterns (PAMP) on invading pathogens, such as LPS and LTA, 
leading to eventual activation of the transcription factor NF-κB, which in turn upregulates 
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production of pro-inflammatory cytokines and chemokines. Infiltrating neutrophils also 
produce proteases, reactive oxygen species (ROS), and reactive nitrogen species (RNS) 
which induce necrotic cell death, leading to extensive lung injury [42]. In this way, 
neutrophils present a "double-edged sword” component of innate immunity in the lung, 
whereby an appropriate neutrophil recruitment response is necessary to limit invasive 
infection, but over-recruitment can lead to irreparable damage to the lung. Therefore, 
inflammation in the lung must be tightly regulated in order to minimize damage from 
invading pathogens, as well as from the host inflammatory response.  
 
Multifunctional role of serum lipoproteins 
 
 The term “serum lipoproteins” encompasses a variety of macromolecular lipid-
protein complexes which can be divided into different classes based on size, density, and 
apolipoprotein associations (Figure 1.3). Among the different serum lipoproteins are 
chylomicrons, chylomicron remnants, very low density lipoprotein (VLDL), low density 
lipoprotein (LDL), and high density lipoprotein (HDL), which function to store and 
transport water-insoluble lipids (cholesterol and triglycerides) throughout the body in a 
water-soluble form.  
The exogenous lipoprotein metabolism pathway starts when dietary lipids are 
incorporated into chylomicrons in the intestine. Processing of chylomicrons by 
lipoprotein lipase in peripheral tissues forms chylomicron remnants which are taken up 
by the liver. The liver is the major source of the three primary lipoprotein particles 
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Figure 1.3 - Differing sizes, apoprotein associations, and functions of serum 
lipoproteins.  
Chylomicrons are made in the intestine for transporting dietary lipids to tissues. Very low 
density lipoprotein (VLDL) is produced in the liver and further metabolized, via 
lipoprotein lipase, to low density lipoprotein (LDL) which is the primary source of 
cholesterol transported from the liver to the peripheral tissues. HDL is responsible for 
reverse cholesterol transport from tissues back to the liver. Adapted from [44]. 
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produced endogenously, which include VLDL, LDL, and HDL. The liver forms VLDL 
which is processed into LDL by lipoprotein lipase in the peripheral tissues. LDL, often 
referred to as “bad cholesterol,” contains the highest percentage cholesterol content of all 
serum lipoproteins, and is responsible for the majority of cholesterol transport from the 
liver to the tissues for uptake via the LDL receptor. In contrast, the reverse cholesterol 
transport particle HDL, often referred to as “good cholesterol,” carries cholesterol from 
the peripheral tissues back to the liver for excretion, and is anti-atherogenic [45]. In the 
case of hyperlipidemia, VLDL and LDL are known to be important contributors to 
atherosclerosis and cardiovascular disease [46-49]. In this respect, statins, used to lower 
LDL cholesterol levels, have become among the most commonly prescribed drugs world-
wide, and have had a significant impact on lowering mortality from cardiovascular 
disease [50]. Statins lower serum cholesterol and triglycerides by inhibiting HMG-CoA 
reductase, a rate-controlling enzyme in the mevalonate metabolic pathway which controls 
cholesterol production [51]. Interestingly, statins have also been associated with 
prevention of morbidity and mortality in sepsis [52]. However, this is likely due to their 
pleiotropic effects on inflammation and the immune system, including effects occurring 
at doses below those required to reduce cholesterol production [53, 54]. 
In addition to cholesterol transport, recent research also supports the role of 
lipoprotein particles as contributors to host innate immunity [55-66]. For example, 
apolipoprotein B (apoB) on VLDL and LDL, and apolipoproteins A1 and A2 on HDL, 
inhibit lipoteichoic acid (LTA)-mediated inflammatory cytokine release [67]. In mice, 
LDL has also been shown to bind lipopolysaccharide (LPS) from Gram-negative bacteria, 
reducing its ability to cause endotoxin induced toxicity, morbidity and mortality [68].  
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Table 1.1 - Apolipoprotein associations with bacterial infection. 
Apolipoprotein Associated Lipid Molecule(s) Association to infection (Host) Publication(s) 
ApoA1 HDL 
Haplotypes protective against sepsis- 
associated acute lung injury (Human) 
 
Anti-microbial against Aeromonas 
hydrophila and immunostimulatory to 
macrophages (Catfish) 
 
Protective against Trypanosoma brucei 
brucei (Human) 
[69-71]    
ApoA2 HDL 
Suppressor of immune activation by LTA 
from S. aureus (Human/Mouse immune 
cells) 
[67] 
ApoC1 VLDL Enhances LPS-induced inflammatory response (Mouse) [72] 
ApoC2 
Chylomicrons 
VLDL 
HDL 
Low levels, a predictive biomarker for 
septicemia and necrotizing entercolitis 
(Human infants) 
[73] 
ApoE Chylomicrons HDL 
Increased susceptibility to Borrelia 
burgdorferi and Borrelia hispanica (ApoE-/- 
mice) 
 
Binds to Legionella pneumophilia and may 
impede host cell penetration and 
intracellular growth, Enhanced 
Porphyromonas gingivalis induced 
neuronal injury (ApoE-/- mice) 
 
Determinant of innate immune response to 
Toll-like receptor ligands in human sepsis 
(Human)  
 
Protective against Cryptosporidium parvum 
infection (Mouse) 
 
Anti-microbial activity against 
Pseudomonas aeruginosa and S. aureus 
[74-79] 
ApoB-100 VLDL LDL 
Inhibits S. aureus quorum-sensing (Mouse) 
 
Suppressor of immune activation by LTA 
from S. aureus (Human/Mouse immune 
cells) 
 
Metabolism of apoB plays a role in acute 
phase reaction against sepsis (Rat) 
[67, 80-82] 
ApoB-48 Chylomicrons Inhibits S. aureus quorum-sensing (Mouse) [83] 
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These and other findings demonstrate that lipoproteins play a role in host innate 
immunity against both Gram-positive and Gram-negative pathogens (Table 1). 
 
Dyslipidemia and pulmonary innate defense 
 
Despite the multifunctional role of lipoproteins, most research on the 
consequences of dyslipidemia has been largely focused on hyperlipidemia, with these 
terms often used interchangeably in the literature, and its impact on cardiovascular 
disease [66]. In contrast, few studies have investigated the consequences of hyper- or 
hypolipidemia on the host innate response to bacterial infection. Recent findings suggest 
that hyperlipidemia results in impaired intrapulmonary host immunity [66, 84], and has 
also been shown to impact lipid content of lung surfactants [85]. Alterations in lung 
surfactant lipid levels may impair the innate defense function of antimicrobial surfactant 
proteins, and have deleterious effects on host defense against bacterial lung infection 
[86]. Similarly, hypolipidemia has epidemiologically been associated with increased 
mortality [87], as well as with increased susceptibility to bacterial pneumonia [88-90]. 
The increased infection risk associated with extremes of dyslipidemia suggests that the 
role of lipoproteins in host innate immune defense may be under-acknowledged. 
However, there is critical gap in knowledge as to how hypolipidemia, as seen during the 
acute phase response during severe illness or traumatic injury [91], may play a role in 
host innate immune pulmonary defense.  
ApoB, the shared structural protein component of chylomicrons, VLDL, and LDL 
(Figure 1.3), was previously shown to protect against Staphylococcus aureus skin and 
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skin structure infection (SSSI) through inhibition of the S. aureus QS system [80, 81, 83] 
(Figure 1.1). In addition, LDL has been reported to directly bind and inactivate S. aureus 
Hla [56], and to a certain extent, the agr-regulated PSMs [65]. Importantly, uptake of 
apoB-containing lipoproteins into the lung by the lung capillary endothelium [92], as well 
as by carriage through binding to leukocytes [93] has been previously demonstrated. 
Although low levels of serum lipoproteins are also associated with increased 
susceptibility to bacterial pneumonia [88-90], the contribution of apoB to host defense in 
the lung has not been thoroughly investigated. 
 
Concluding remarks and hypothesis 
 
As outlined above, the vast majority of research in dyslipidemia has been focused 
on hyperlipidemia, due to its importance in causing cardiovascular disease, but recent 
research supports the role of lipoprotein particles as contributors to host innate immunity 
against infectious disease. Given the increase in pneumonia caused by MRSA, and the 
association between hypolipidemia and susceptibility to bacterial pneumonia [88-90], we 
postulated that hypolipidemia, which can result from the acute phase response during 
severe illness, may impair host innate immune pulmonary defense (Figure 1.4).  
Specifically of interest to the body of research presented herein, apoB quenches S. 
aureus QS, thereby limiting the bacteria’s ability to turn on a myriad of virulence factors 
necessary for invasive infection. To test the hypothesis that hypolipidemia impairs innate  
14 
 
 
 
  
Figure 1.4 - Do serum levels of apoB-containing lipoproteins contribute to host innate 
pulmonary immune defense against S. aureus infection?  
We hypothesized that in a hypolididemic state (right panel), as seen post trauma and 
during the acute phase response, lack of apoB-containing lipoproteins in the lung and 
airway would lead to lack of control of S. aureus QS during pulmonary infection, as 
compared to a normal lipidemic state (left panel). 
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pulmonary immune defense against S. aureus agr-mediated infection (Figure 1.4), we 
used a sub-lethal model of S. aureus pneumonia in pharmacologically-induced and 
genetic mouse models of lipoprotein deficiency. In Chapter 2, we detail optimization of 
our chosen S. aureus pneumonia infection model, the importance of consistent 
inoculation methodologies for pulmonary infection, procedural considerations and their 
effects on consistency of bacterial delivery to the lung. More specifically, we discuss 
different infection methods, the effects of intranasal delivery volume on initial infection, 
how the choice of anesthetic may effect or confound results, and choosing relevant time 
points for our model of infection. In Chapter 3, we show that lipoprotein deficiency 
impairs host control of S. aureus QS in the lung, resulting in agr-dependent increases in 
pro-inflammatory cytokine production and neutrophil influx in the lung. Furthermore, we 
show that apoB inhibits agr-dependent inflammatory cytokine expression by human 
alveolar epithelial cells, supporting a role for apoB in limiting QS-dependent virulence 
and inflammation during human lung infection. Finally, in Chapter 4, we discuss 
considerations for and present data from experimental efforts to use apoB-containing 
serum lipoproteins therapeutically in lipoprotein deficient mice infected with S. aureus 
pneumonia. 
Together, the work reported here advances our understanding of the negative 
impact of dyslipidemia on pulmonary host innate defense, and may have broad 
implications for hypolipidemia in increased susceptibility to post-trauma pneumonia 
caused by both Gram positive and Gram negative pathogens.  
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Chapter 2 – Staphylococcus aureus pneumonia mouse model dosing 
strategy 
 
Introduction 
 
Mouse models of infection are an important tool for studying infectious agents 
and their sequelae. Rapidly reproducing, inbred mouse strains allow for ease of study in 
genetically identical backgrounds, facilitating investigation of host-pathogen interactions 
via genetics-based approaches. However, using mouse models also comes with many 
caveats, including choosing a proper model to elucidate answers to questions about 
human disease, or about relevant host-pathogen interactions. Discussed here will be 
different accepted practices for using mice as a model organism for studying bacterial 
pneumonia and the advantages and pitfalls of different infection methods. We will also 
describe the approach we employed to optimize the consistency of S. aureus intranasal 
infection looking specifically at the effects of anesthetic on bacterial delivery and S. 
aureus infection outcomes, the importance of choosing observational time points for a 
mouse model of S. aureus pneumonia relevant to the effects of lipoprotein contributions 
to defense against S. aureus in the lung, and intranasal dose delivery volumes. 
 
Inoculum delivery methods for bacterial pneumonia 
 
Aerosol exposure to pathogens mirrors airborne exposure scenarios of infection 
[94]. Animals are placed in an enclosed chamber, and aerosolized pathogen is pulled into 
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the chamber. This method has the advantage of requiring no anesthesia, and provides 
consistent pathogen deposition into the lung across experimental animal groups [95-97]. 
Concentrations for appropriate deposition of pathogen into the lungs can be determined 
by adjusting exposure time and aerosol flow into the chamber.  However, there are many 
caveats for aerosol exposure methods. They generally require costly exposure systems, 
and in the case of more dangerous pathogens, can create costly containment 
considerations. Additionally, fairly large inoculation volumes and concentrations are 
required relative to actual pathogen delivery into the lung, creating a limitation on 
inoculation level in the lung. Whole-body exposure systems come with the added concern 
that off-target inoculation sites will confound experimental results [95], and while nose-
only aerosol exposure systems exist, they are more expensive and require additional 
costly equipment and time for animal restraint. 
Intratracheal infection mouse models of pneumonia mirror lower respiratory tract 
infections. Two typical methods for this inoculation method include transtracheal 
injection and peroral intubation [94]. Transtracheal injection requires anesthesia followed 
by surgical exposure of the trachea, by which a small gauge needle is inserted and the 
infection inoculum is delivered directly into the trachea before suturing of the surgical 
wound. Peroral intubation avoids potential complications of surgery by delivering 
inoculum via blunted needle injection after oral insertion of the needle directly above the 
tracheal bifurcation. Whereas both these methods allow for larger bolus dose delivery to 
the lung than aerosol administration (discussed above) or intransal infection (discussed 
below) [95, 98], the need for prolonged general anesthesia combined with longer delays 
between inoculation of individual animals can lead to confounding non-inoculum 
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dependent effects. More specifically challenges include anesthesia/aspiration induced 
death, and difficulties maintaining consistency of data collection at specific post-infection 
time points. The latter is particularly important for short, acute infection models such as 
utilized in Chapter 3. 
Finally, intranasal infection is another commonly used practice for infecting mice 
with a variety of pathogens [13, 99, 100], and may be more relevant in modeling 
organisms which infect both the upper and lower respiratory tract. The first intranasal S. 
aureus pneumonia model in immunocompetent mice was described by Bubeck-
Wardenburg et al. [13]. Since this method was published it has been become standard 
practice amongst the S. aureus pneumonia research community [101-103]. In this 
approach, mice are anesthetized and the inoculum suspension is introduced into the nares 
through aspiration. While this method allows for simple and quick introduction of 
pathogens into the mouse airway, it is the most highly variable method for pathogen 
delivery to the lung [94], with little control over where pathogens are deposited in the 
airway or final inoculum delivered to desired site of infection.  
 
Results and Discussion 
 
Choice of anesthetic impacts intranasal administration of S. aureus  
Since intranasal infection requires aspiration by the animal, anesthetic effects on 
respiration rates may cause variable levels of inoculum delivery to the lung [104, 105]. 
Physical effects of particular anesthetics can have profound impact on variation in 
inoculum delivery and infection results [94]. In a recent study looking at dosing 
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efficiency of fluorescent F. tularensis via whole body imaging, mice anesthetized with 
ketamine/xylazine maintained a steadier breathing pattern than those anesthetized with 
short periods of inhaled isoflurane [106]. Despite this, more efficient delivery of 
fluorescent F. tularensis to the lungs was seen in mice anesthetized with isoflurane [106]. 
Additionally, our own observations described below indicate that anesthetic choice can 
have profound impacts on weight loss (often used as a measure of morbidity) and 
infection outcomes. There are a very limited number of studies observing effects of 
different anesthetics on infection outcomes. Interestingly, despite all these variables, 
there is a low overall reporting in the literature of actual S. aureus inoculum delivery to 
the lung using intranasal infection [106], and though the anesthetic used for infection is 
typically reported, the potential impacts of anesthetic choice are not discussed. 
In our own studies comparing intranasal inoculation of S. aureus following 
parenteral metamine/xylazine or inhaled isoflurane, we found that ketamine/xylazine led 
to significant drops in body weight compared to isoflurane (Figure 2.1A). Additionally, 
ketamine/xylazine required petroleum jelly to keep the animals’ eyes from drying out 
during recovery from anesthesia. Together, this appeared to increase overall morbidity 
scoring (consisting of observational measurements of grooming, natural, and provoked 
behavior) related to grooming, due to petroleum jelly on and around the eyes, and weight 
loss, leading to more moribund mice overall as compared to infection using isoflurane 
(Figure 2.1B). We would hypothesize that the longer recovery time from 
ketamine/xylazine, compared to isoflurane, leads to significant anesthesia induced weight  
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Figure 2.1 - Comparison of weight loss and clinical scores using parenteral 
ketamine/xylazine or inhaled isoflurane in mice infected intranasally with S. aureus. 
(A) Comparison of weight loss at six hours post intranasal infection with S. aureus, of 
vehicle-treated vs. 4-aminopyrizolo[3,4-d]pyrimidine (4APP)-treated mice, anesthetized 
for infection using ketamine/xylazine or isoflurane. (B) Comparison of relative morbidity 
based on clinical scores at six hours post intranasal infection with S. aureus, of vehicle-
treated vs. 4APP-treated mice, anesthetized for infection using ketamine/xylazine or 
isoflurane. 
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loss during recovery and infection. Additionally, observational morbidity measurements 
(specifically grooming) seemed to be increased based on lack of grooming in mice that 
had petroleum jelly still on and around the eyes (data not shown). 
 
Intranasal dose delivery volumes 
Intranasal dose delivery volumes have been shown to have dramatic impacts on 
mouse survival during infection. Profound effects related to the deposition site of the 
delivered pathogen have also been observed, with lower volumes tending to preferentially 
deposit in the upper respiratory tract [104-106]. However, there is a surprising lack of 
literature specifically describing the efficiency of delivery into the lung employing 
different intranasal dosing volumes for infectious agents. In a study by Miller et al. [84], 
they found that delivery volumes between 50 µL to 100 µL were more efficient at 
delivery of fluorescent Francisella tularensis into the lung, compared to volumes of 10 
µL which resulted in more deposition into the upper respiratory tract. In the case of 
intranasal instillation of S. aureus, delivery volumes between 20 µL to 50 µL are 
commonly reported [16, 22], however delivery efficiency to the lung at these volumes is 
seldom provided [13]. Specifically, the range of commonly reported intranasal bacterial 
dosing volumes (2 µL to 100µL), may have dramatically different effects on aspiration of 
and general inoculum loss through expulsion by normal breathing.  
We observed that delivery volumes above 15 µL required multiple aspiration 
steps to limit loss through expulsion by normal breathing, and that splitting a 30 µL 
volume delivered in two 15 µL boluses (one to each nare) had less apparent loss of 
inhaled volume through expulsion from the airway (data not shown). However, given 
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previous findings that volumes above 50 µL showed more efficient bacterial delivery to 
the lung during intranasal infection [106], we implemented a “wash down” of the initial 
bacterial delivery bolus with two subsequent aspirations of normal saline (15 µL in each 
nare), for a total delivery volume of 60 µL. Using this method of intranasal infection, we 
found consistent delivery of bacteria to the lung of ~10-20% of initial inoculum (data not 
shown). 
 
Choosing observational time points in a mouse model of S. aureus 
pneumonia 
Though mice are often used as models of infection, due to the ease of use and 
wide availability of many potentially clinically relevant genetic knockout mouse models, 
one must be careful in selecting an appropriate model for testing a specific hypothesis. 
For example, mouse models of S. aureus infection are often criticized because of their 
lack of clinical relevance, since S. aureus is not a regular occurring commensal of mice, 
and since mice show particular resilience against many of the relevant human virulence 
factors [107]. Indeed, the titers needed to achieve significant disease in a mouse model of 
S. aureus pneumonia are quite high (2-4 x 108 CFU, [107]). For our specific purposes, 
established protocols for intranasal infection with S. aureus, along with two established 
models of lowered serum lipoproteins in mice (discussed in detail in Chapter 3), have 
allowed us the ability to model infection during the acute phase response of humans, as 
related to reductions in serum lipoprotein levels. We found that an increase in a half-log 
of S, aureus inoculum titer can make the difference between 24 hour mortality (data not 
shown), or an almost three log reduction in CFUs in the lung by 24 hours (Figure 2.2A).  
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Figure 2.2 - Clearance of S. aureus from the lung, and weight loss differences at 
different time-points of pneumonia.  
(A) Differences in CFUs present in the lung at 6 and 24 hours post-infection, of 
lipoprotein deficient and control mice, infected intranasally with LAC. (B) Differences in 
percentage weight loss at 6 and 24 hours, of lipoprotein deficient and control mice, 
infected intranasally with LAC. 
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Previous research has also shown that serum lipoprotein levels increase in the 
lungs of mice during S. aureus pulmonary infection at 6 hours post-infection [108], as 
well as showing increases in inflammatory cytokines (such as IL-1β) in the lung at this 
early time point of infection. Given this, and our hypothesis that serum lipoproteins play 
a role in innate immunity in the lung during S. aureus infection, a 6 hour model of 
infection was chosen as the most relevant time point to assess early control of S. aureus 
QS in the lung. Importantly, we observed that at 6 hours post infection, infected mice still 
had a substantial portion of the initial infection inoculum present in the lung (Figure 
2.2A), and lipoprotein deficient mice showed increased weight-loss compared to controls 
(Figure 2.2B). Based on this and previous observations about serum lipoproteins in the 
lung and increases in inflammation at this infection time point, we predicted that the 
contribution of lipoproteins to pulmonary innate immunity may be best examined at 6 
hours post-infection. 
 
Conclusions 
 
Here we emphasize the importance of publishing detailed protocols for pulmonary 
infection with bacteria. The described comparative studies resulted in the following 
protocol:  
1) Isolate 4 mice into an isoflurane chamber and anesthetize using 3.5 L/min of 
isoflurane with 2.5 L/min O2 flow. 
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2) Remove the first mouse after 5 min in isoflurane chamber, and holding the mouse 
at a ~45 ̊ angle with the anterior positioned towards the floor, pipette 15 µl of 
saline containing ~2-4 x 108 CFU per 30 µl, onto the left nare. 
3) After the mouse has inhaled the first bolus, repeat this for the right nare. 
4) Repeat steps 2 and 4 using sterile saline. 
5) After the mouse has aspirated the final saline dose, hold the mouse at a ~45 ̊ angle 
with the anterior positioned towards the floor, for an additional 1 min. 
6) Place mouse prostrate on the floor of housing cage. 
7) Repeat this same process for the remaining mice in the isoflurane chamber. 
This protocol resulted in a very consistent bacterial delivery to lung (~10-20%) of initial 
bacterial suspension titer across all groups and experiments. 
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Chapter 3 – Serum Lipoproteins are Critical for Pulmonary Innate 
Defense against Staphylococcus aureus Quorum-sensing 
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Abstract 
 
Hyperlipidemia has been extensively studied in the context of atherosclerosis, 
whereas the potential health consequences of the opposite extreme, hypolipidemia, 
remain largely uninvestigated. Circulating lipoproteins are essential carriers of insoluble 
lipid molecules and are increasingly recognized as innate immune effectors. Importantly, 
severe hypolipidemia, which may occur with trauma or critical illness, is clinically 
associated with bacterial pneumonia. To test the hypothesis that circulating lipoproteins 
are essential for optimal host innate defense in the lung, we used lipoprotein deficient 
mice and a mouse model of Staphylococcus aureus pneumonia in which invasive 
infection requires virulence factor expression controlled by the accessory gene regulator 
(agr) operon. Activation of agr and subsequent virulence factor expression is inhibited by 
apolipoprotein B, the structural protein of low density lipoprotein, which binds and 
sequesters the secreted agr-signaling peptide (AIP). Here we report that lipoprotein 
deficiency impairs early pulmonary innate defense against S. aureus quorum-sensing 
dependent pathogenesis. Specifically, apoB levels in the lung early post-infection are 
significantly reduced with lipoprotein deficiency, coinciding with impaired host control 
of S. aureus agr-signaling and increased agr-dependent morbidity (weight loss) and 
inflammation. Given that lipoproteins also inhibit LTA- and LPS-mediated inflammation, 
these results suggest that hypolipidemia may broadly impact post-trauma pneumonia 
susceptibility to both Gram positive and Gram negative pathogens. Together with 
previous reports demonstrating that hyperlipidemia also impairs lung innate defense, 
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these results suggest that maintenance of normal serum lipoprotein levels is necessary for 
optimal host innate defense in the lung.  
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Introduction  
 
Hyperlipidemia is a clinical syndrome with high circulating levels of cholesterol, 
triglycerides and the lipoprotein particles which carry them, including very low and low 
density lipoproteins (VLDL, LDL) [87]. Hyperlipidemia is a risk factor for 
cardiovascular disease [109, 110], yet serum lipoproteins also contribute to host innate 
defense against infection [57, 111]. Interestingly, hyperlipidemia results in impaired 
intrapulmonary host immunity [84], suggesting that maintenance of normal circulating 
cholesterol and lipoprotein levels is crucial for optimal host innate defense in the lung. 
Although severe hypolipidemia, which often accompanies the acute phase response 
(APR) following surgery or trauma (reviewed in [112-114]), has been associated with 
bacterial pneumonia [88-90], a critical gap in knowledge remains regarding the impact of 
extremely low serum lipoprotein levels on host innate defense in the lung. 
Staphylococcus aureus, and methicillin-resistant S. aureus (MRSA) in particular, 
accounts for 20% to 40% of hospital-acquired pneumonia (HAP) cases in the USA, as 
well as a growing number of cases of community-acquired pneumonia (CAP) [115-117]. 
Invasive pulmonary infection caused by S. aureus requires the expression of virulence 
factors controlled by the accessory gene regulator (agr) operon [13, 118-120], which 
encodes a two-component quorum-sensing (QS) system for bacterial communication and 
coordinated gene expression (reviewed in [8, 121]). QS is facilitated by secretion of a 
cyclic autoinducing peptide (AIP), which binds to and activates its cognate surface 
receptor AgrC. This in turn leads to expression of over 200 virulence factors [122], many 
of which are pre- and post-transcriptionally regulated by a small RNA molecule, called 
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RNAIII, produced by transcription from the agr P3 promoter [8, 121]. Importantly, 
apolipoprotein B (apoB), the sole protein component of LDL lipoprotein particles, and 
not other serum apoproteins or associated lipids, binds and sequesters AIP, thereby 
inhibiting agr-signaling and limiting pathogenesis during S. aureus skin infection [80, 83, 
123]. However, the impact of apoB deficiency and hypolipidemia on host innate defense 
in the lung, and against S. aureus pneumonia in particular, has not been investigated. We 
hypothesized that serum lipoproteins would contribute to pulmonary host defense against 
S. aureus QS and agr-mediated inflammation. 
Here we used a sub-lethal model of S. aureus pneumonia to demonstrate that 
severe hypolipidemia impairs the early host innate defense response to lung infection. 
Specifically, lipoprotein deficiency impairs host control of S. aureus QS in the lung, 
resulting in agr-dependent increases in pulmonary pro-inflammatory cytokine production 
and neutrophil influx. Furthermore, apoB inhibits agr-dependent inflammatory cytokine 
expression by human alveolar epithelial cells, supporting a role for apoB in limiting QS-
dependent virulence and inflammation during human lung infection. Given that serum 
lipoproteins also limit inflammation via sequestration of lipotechoic acid (LTA) and 
lipopolysaccharide (LPS) [124-126], these studies may have broad implications for 
hypolipidemia in increased susceptibility to post-trauma pneumonia caused by both Gram 
positive and Gram negative pathogens.  
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Materials and Methods 
 
Bacterial strains and growth conditions 
USA300 LAC and its isogenic agr deletion mutant (USA300 LACΔagr) were provided 
by Dr. Frank DeLeo (Rocky Mountain Laboratories, NIAID/NIH, Hamilton, MT) and Dr. 
Michael Otto (NIAID/NIH, Bethesda, MD), LACΔhla was provided by Dr. Juliane 
Bubeck-Wardenburg (University of Chicago, Department of Microbiology, Chicago, IL) 
and AH1677 agr::P3-yfp (USA300 LACyfp) was provided by Dr. Alex Horswill 
(University of Iowa, Department of Microbiology, Carver College of Medicine). Bacteria 
were grown in trypticase soy broth (TSB) and early exponential phase frozen stocks were 
prepared as previously described [127]. CFU of frozen stocks were determined by plating 
of serial dilutions on blood agar (BD Biosciences, Franklin Lakes, NJ).  
 
Mouse model of S. aureus pneumonia 
Animal work was carried out at the AAALAC accredited Animal Research Facility of the 
University of New Mexico Health Sciences Center in accordance with recommendations 
in the Eighth Edition of The Guide for the Care and Use of Laboratory Animals and the 
USA Animal Welfare Act. The protocol was approved by the Institutional Animal Care 
and Use Committee (IACUC) of the University of New Mexico. Eight to twelve week 
old male mice (C57BL/6, Pcsk9−/− on the B6 x 129 background, and B6 x 129 wild-type) 
were purchased from Jackson Laboratories (Bar Harbor, ME). Mice receiving 4-
aminopyrazole-(3,4-D)pyrimidine (4APP) treatment were injected i.p. with 100 µl of 
5.15 mg/ml 4APP (Sigma-Aldrich, St. Louis, MO) prepared as previously described [80, 
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123], or buffer control at 48 and 24 hours before infection, as well as at the time of 
infection. Reductions in serum cholesterol were determined using Infinity Cholesterol 
Liquid Stable Reagent (Thermo Scientific, Middletown, VA) according to manufacturer’s 
directions.  
 
The mouse model of S. aureus pneumonia was performed as previously described [13]. 
Briefly, mice were anesthetized by isoflurane inhalation and 30 µl of sterile saline 
containing ~4 x 108 CFU of S. aureus was administered intranasally, followed by an 
additional 30 µl of saline alone. Mice were weighed at the time of infection and again 
prior to sacrifice. At 6 hours post-infection, mice were sacrificed by CO2 asphyxiation 
and blood and tissues collected. For CFU determinations, right lungs were collected in 
bead-beating tubes containing 2.3-mm Zirconia/Silica beads (BioSpec Products, 
Bartlesville, OK) in 1 ml HBSS- (Life Technologies, Grand Island, NY) with 0.2% 
human serum albumin (Sigma-Aldrich, St. Louis, MO), and lung tissue disrupted for 1 
min using a Mini-Bead Beater-24 (Biospec). Homogenates were diluted 1:10 in PBS with 
0.1% Triton X-100, sonicated, and serial dilutions plated on blood agar (BD Biosciences, 
Franklin Lakes, NJ). For agr::P3-YFP promoter activation assays, bacteria from diluted 
homogenates were pelleted by centrifugation and fixed for 10 min with 1% 
paraformaldehyde containing 25mM CaCl2. Promoter activation was determined by 
measuring mean channel fluorescence (MCF) by flow cytometry (Accuri C6, BD Accuri 
Cytometers, Ann Arbor, MI). For cytokine and Western blot analyses, lung homogenates 
were clarified by centrifugation at 12,500 x g and supernatant was stored at -80 °C until 
use as described below. For transcription analyses, left lungs were harvested, 
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immediately placed into 1.8 mL of RNAlater (Qiagen, Valencia, CA), and frozen at -
80°C.  
 
A549 cell exposure to bacterial supernatant  
For A549 assays, bacteria were cultured in TSB (5 mL with 10:1 air to volume ratio) for 
6 hours at 37 °C with shaking and with or without 100 nM human LDL (hLDL). Bacteria 
were then pelleted by centrifugation and supernatants filter sterilized by passage through 
0.2 µm filters, aliquoted, and frozen at -80 °C until use. A549 human alveolar epithelial 
cells were grown to 80-90% confluence in 12-well plates in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% heat-inactivated Fetal Bovine Serum (HI-
FBS) and penicillin/streptomycin. Twenty-four hours prior to use, cell culture medium 
was changed to DMEM with 10% human lipoprotein deficient serum with 
penicillin/streptomycin. Sterile bacterial supernatants were thawed, diluted to working 
concentrations in TSB, and added to A549 cells at a 1:10 dilution in cell culture media. 
Post-culture hLDL was added to respective supernatants at 100 nM concentration prior to 
addition to A549 cells. Cells were incubated at 37 °C for 4 hours. At 4 hours post-
exposure, cell culture supernatants were collected and frozen at -80 °C for future 
analysis. To collect RNA, cells were immediately lysed with Qiagen RLT buffer with 1% 
β-mercaptoethanol and QIAshredder spin columns (Qiagen, Valencia, CA). RNA was 
processed using an RNeasy Mini kit, according to the manufacturer’s Animal Cell Spin 
protocol (Qiagen, Valencia, CA). 
 
Quantification of cytokines and myeloperoxidase ELISA 
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Cytokines were measured in cell culture supernatant or clarified supernatant from mouse 
lung homogenates using custom designed Milliplex Cytokine Magnetic kits according to 
the manufacturer’s specifications (Millipore, Billerica, MA). Cell culture supernatants 
were pooled from identically treated triplicates. Myeloperoxidase was also measured in 
clarified supernatants using the Mouse Myeloperoxidase DuoSet ELISA (R&D Systems, 
Minneapolis, MN) according to manufacturer’s directions.  
 
Western blot analyses 
Clarified lung homogenate supernatants were quick thawed (37°C) and protein 
concentrations determined by A280 absorption (Nanodrop 100 Spectrophotometer, 
Thermo Fisher Scientific, Wilmington, DE). For apoB Western blots, equivalent amounts 
of total protein were separated by SDS-PAGE on 3-8% Tris-Acetate gels (Novex Life 
Technologies, Grand Island, NY) prior to transfer to polyvinylidene fluoride (PVDF) 
membranes. Membranes were blocked with 5% non-fat milk in TBS (20mM Tris pH 7.5, 
150 mM NaCl) containing 0.1% Tween-20 (TBST), then probed with rabbit anti-apoB 
antibody (Abcam, Cambridge, MA). Unbound antibody was removed by triplicate 5 min 
washes with TBST, and membranes developed using goat anti-rabbit IgG-alkaline 
phosphatase-conjugated secondary antibody (KPL, Gaithersburg, MD) and 1-Step 
nitroblue tetrazolium (NBT)/5-bromo-4-chloro-3-indolyl-phosphate (BCIP) (Thermo 
Scientific).  
 
For Western blot analysis of secreted Hla in bacterial supernatants applied to A549 cells 
(above), equivalent amounts of total protein were separated by SDS-PAGE on 4-12% 
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Bolt gels (Novex Life Technologies, Grand Island, NY) prior to transfer to 
polyvinylidene fluoride (PVDF) membranes and overnight blocking. Membranes were 
probed with mouse anti-Hla mAb (Integrated BioTherapeutics, Gaithersburg, MD), 
followed by goat anti-rabbit IgG poly-horseradish peroxidase (Thermo Fisher Scientific). 
Blots were developed using Thermo Pierce SuperSignal West Pico Chemiluminescent 
substrate (Thermo Fisher Scientific). All blots were imaged using a ProteinSimple 
FluorChem R instrument and quantified with AlphaView software (Protein Simple, Santa 
Clara, CA).  
 
Rabbit erythrocyte lysis assay 
Sterile bacterial culture supernatants prepared as described above and used for A549 
cytokine induction assays were tested for hemolytic activity as previously described 
[128]. Briefly, a 4% solution of rabbit RBCs in PBS was incubated at 37 °C for 1 h with 
2-fold serial dilutions of sterile-filtered bacterial supernatant. Lysis was determined by 
the A450 of the resulting RBC supernatant. Data were analyzed by nonlinear regression 
and are shown as the HA50 which equals 1/ the log of the dilution needed for 50% 
complete lysis. 
 
Quantitative RT-PCR 
For bacterial RNA isolation, bronchial alveolar lavage fluid (BALF) was collected as 
described below but in a 10-fold volume of RNAlater (Qiagen) and frozen at -80 °C for 
later processing. After thawing, bacteria were pelleted by centrifugation, RNAlater was 
aspirated, and pellets were incubated with 100 µL Tris-EDTA (TE) buffer, with 20 
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µL/mL proteinase K (Qiagen) and 20 µg/mL of lysostaphin for 10 min. Thawed lungs 
were removed from RNAlater and RNA extracted using Qiazol according to 
manufacturer’s directions (Qiagen). RNA isolation from cell culture was performed as 
described above. An RNAeasy Mini kit (Qiagen) was used for RNA purification and 
cDNA was generated using a high-capacity cDNA RT kit with RNAse inhibitor together 
with random hexamer primers (Applied Biosystems, Foster City, CA). Taqman Gene 
Expression master mix (Applied Biosystems) and an ABI7000 Real-Timer PCR system 
were used for quantitative PCR. Prime Time Predesigned qPCR primers and probes 
(Integrated DNA Technologies, Coralville, IA) were used for transcriptional analyses of 
mouse hprt, il-1b, mip-2 and il-6, and for human hrpt and il-8. Primers and probes for 
quantification of S. aureus 16S, RNAIII and lukS were previously described [129]. Gene 
expression was quantified using SDS RQ Manager Version 1.2.2 software (Applied 
Biosystems) relative to mouse or human hprt, and S. aureus 16S, as appropriate.  
 
Cell influx analysis of bronchial alveolar lavage fluid 
BALF was collected from sacrificed mice by intratracheal lavage, using three sequential 
washes (700 µl each) with ice cold Dulbecco’s Phosphate-Buffered Saline (2.67 mM 
KCl, 1.47 mM KH2PO4, 138 mM NaCl, 8.1 mM Na2HPO4) (Corning, Corning, NY). 
Total cell count and live/dead counts were determined by trypan blue staining using a TC 
20 Automated Cell Counter System (Biorad, Hercules, CA). For immunostaining, cells 
were centrifuged at 800 x g for 3 min then pelleted cells resuspended in cold PBS with 
0.5% BSA and 0.075% sodium azide. Cells were blocked for 30 min with 2% BSA, 
followed by a 1-h, 4°C incubation with anti-mouse Ly6G (neutrophils) (BioXCell, West 
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Lebanon, NH) conjugated to AlexFluor 488 (Protein labeling kit, Molecular Probes Inc., 
Eugene, OR), anti-mouse CD11c-PE (alveolar macrophages) (Biolegend, San Diego, 
CA), or isotype controls. Cells were washed with PBS prior to analysis by flow 
cytometry (Accuri C6, BD Accuri Cytometers).  
 
 Statistical analyses 
All data were analyzed using Prism 5.0 software for Windows (GraphPad Software Inc., 
La Jolla, CA). Parametric data were analyzed using the two-tailed Student’s t-test or 
ANOVA with either Dunnett’s post-hoc test or Bonferroni’s multiple comparison test, 
and are displayed as the mean ± SEM. Non-parametric data were analyzed by the Mann-
Whitney U test and displayed as the median plus 5th-95th percentiles.  
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Results 
 
Lipoprotein deficiency impairs host control of S. aureus QS in the lung 
Since lipoproteins are detectable in lungs shortly after intranasal infection with S. 
aureus [108] and apoB on LDL binds S. aureus AIP and inhibits agr-activation [80, 83, 
123], we predicted that decreased circulating lipoprotein levels would result in impaired 
control of S. aureus QS in the lung. To address this, we compared S. aureus agr-
activation in the lungs of mice with reduced apoB levels versus controls. Given that 
APOB deletion is embryonic lethal [130], we used pharmacological treatment with 4-
aminopyrazole-(3,4-D)pyrimidine (4APP), which inhibits lipoprotein secretion from the 
liver [131], and Pcsk9-/- mice, which have reduced circulating LDL levels due to 
overexpression of the LDL receptor (LDLR) [132], as models of apoB deficiency. Both 
models have an approximately 50% reduction in apoB measured in the serum (Figure 
3.1A,B), consistent with those of trauma patients at risk of infection [114]. Using a sub-
lethal challenge model [13], we intranasally infected mice with a reporter strain of the 
agr+ clinical isolate LAC, which expresses YFP under the control of the agr::P3 
promoter [133]. We measured agr-activation at six hours post-infection, at which time 
agr activation is detectable in the lung, as are differences in lung pathogenesis and 
bacterial burden between mice infected with agr+ versus ∆agr isolates [118, 134]. As 
expected, agr::P3 promoter activation was significantly increased in the lungs of both 
4APP-treated and Pcsk9-/- mice compared to controls (Figure 3.2A,D). In addition, 
bacteria in BALF collected from LAC infected 4APP-treated mice showed increased  
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Figure 3.1 - 4APP-treated and Pcsk9
-/- 
mice show similar reductions in serum 
cholesterol and apoB.  
(A) Quantification of mouse serum cholesterol. (B) Western blot for serum apoB (left) 
and apoB quantification by relative band intensity versus control (right). Data shown as 
mean ± SEM. N= four mice per group. *, p≤0.05; ***, p≤0.001; ****, p≤0.0001, 
Student’s t-test. 
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Figure 3.2 - Reduction of circulating lipoproteins increases pulmonary agr-signaling 
and weight loss.  
Vehicle- or 4APP-treated (A-C, white and gray bars, respectively) and B6 x 129 (WT) or 
Pcsk9
-/- 
mice (D-F, white and gray bars, respectively) were intranasally infected with 
agr::P3-YFP LAC or LAC∆agr (4 x 10
8
 CFU) and analyses performed at 6 hours post-
infection. (A, D) Flow cytometric quantification of S. aureus agr::P3 promoter activation 
in the lungs of lipoprotein deficient mice relative to controls (N=6 mice per group). Data 
shown as mean ± SEM. ***, p≤0.001; ****, p≤0.0001, Student’s t-test. (B, E) Weight 
loss (g) of infected lipoprotein deficient mice versus controls (N ≥ 8 mice per group from 
at least two independent experiments). (C, F) Bacterial burden (Log CFU) in the lung 
(N=8 mice per group from two independent experiments). (B-C, E-F) Data shown are 
median plus 5th-95th percentiles. ns, not significant; *, p≤0.05, **, p≤0.01, Mann-
Whitney test.  
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transcription of agr-regulated RNAIII and lukS-PV, the latter encoding the Panton-
Valentine leukocidin (PVL) (Supplemental Figure 3.1). Furthermore, 4APP-treated and 
Pcsk9-/- mice infected with LAC, but not with an isogenic agr mutant (LAC∆agr), 
showed increased weight loss, used as a measure of morbidity, compared to vehicle-
treated and WT controls, respectively (Figure 3.2B,E), suggesting increased virulence in 
the lipoprotein deficient mice due to an inability to control agr-signaling. Importantly, 
differences in QS and weight loss at this time point were not the result of increased 
bacterial burden, as the number of CFUs in the lungs of lipoprotein deficient mice did not 
differ from that of controls (Figure 3.2C,F). Therefore, these results suggest that serum 
lipoproteins contribute to host control of S. aureus QS-dependent virulence in the lungs 
and that this contribution is independent of host control of bacterial burden. 
 
Serum lipoprotein deficiency impacts post-infection lung apoB 
concentrations  
Increased agr-signaling in the lungs of S. aureus infected lipoprotein deficient 
mice (Figure 3.2A,D) suggested that these mice would have decreased apoB present in 
the lungs compared to lipoprotein sufficient controls. As suggested, LAC-infected Pcsk9-
/- mice showed significantly decreased apoB in the lungs at six hours post-infection 
compared to wild-type controls (Figure 3.3A,B). Similarly, compared to vehicle-treated 
mice, BALF from mice treated with 4APP and infected with LAC also showed 
significant reductions in apoB at the six hour time point (Figure 3.3C,D). In contrast, 
differences in apoB levels in BALF from mice infected with LAC∆agr did not reach  
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Figure 3.3 - Reduction of serum lipoproteins decreases post-infection apoB levels in 
the lung.  
(A) Western blot analysis of apoB and (B) relative quantification of apoB versus serum 
control in whole lung homogenates of B6 x 129 (WT) or Pcsk9
-/- 
mice 6 hours following 
intranasal infection with LAC (N=6 mice per group). (C) Western blot analysis and (D) 
relative quantification of apoB in BALF from vehicle- or 4APP-treated mice 6 hours 
following intranasal infection with LAC or LAC∆agr (N=6 and 3 mice per group, 
respectively). Data shown are mean ± SEM. ns, not significant; *, p≤0.05, **, p≤0.01, 
Student’s t-test. 
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statistical significance. Together, these data suggest that the presence of apoB in the lung 
during S. aureus infection, and thus its ability to control agr-signaling in the lung, is 
dependent upon circulating lipoprotein concentrations. 
 
Lipoproteins regulate both agr-dependent and agr-independent 
induction of pro-inflammatory cytokines in the lung  
S. aureus stimulates the release of a variety of cytokines and chemokines in the 
lungs of infected mice, including cytokines produced in response to agr-regulated 
virulence factors [13, 18, 101, 108, 119, 135, 136]. In particular, expression of the agr-
regulated virulence factor alpha-hemolysin (Hla), a pore-forming toxin, induces 
pulmonary release of the pro-inflammatory cytokine IL-1β [18, 101], suggesting there 
would be an agr- and Hla-dependent increase in IL-1β in the lungs of lipoprotein 
deficient mice compared to controls. As predicted, 4APP-treated mice infected with 
LAC, but not with LAC∆agr or LAC∆hla, had significantly increased pulmonary IL-1β 
levels at six hours post-infection compared to vehicle-treated mice (Figure 3.4A), 
consistent with increased morbidity (weight loss) relative to vehicle controls only with 
LAC infection (Figure 3.2B, 3.4B). Also, as seen for LAC and LAC∆agr infected mice, 
bacterial burden did not differ between 4APP- and vehicle-treated mice infected with 
LAC∆hla (Figure 3.4C). Interestingly, IL-1β expression was reduced in lipoprotein 
deficient mice infected with LAC∆agr (Figure 3.4A), although the mechanism driving 
this response remains unclear. Therefore, although Hla expression in lung homogenate of  
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Figure 3.4- Lipoproteins limit Hla-dependent pulmonary IL-1β production. 
 (A) IL-1β levels in whole lung homogenate from vehicle- and 4APP-treated mice (white 
and gray bars, respectively) 6 hours following intranasal infection with the indicated 
isolate. Data shown are mean ± SEM. ns, not significant; *, p≤0.05, Student’s t-test. (B) 
Weight loss (g) of infected lipoprotein deficient mice versus controls (N=8 mice per 
group from two independent experiments. (C) Bacterial burden (Log CFU) in the lung. 
N=8 mice per group. (B-C) Data shown are median plus 5th-95th percentiles. ns, not 
significant, Mann-Whitney test.  
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LAC infected mice was below the limit of detection at six hours post-infection (Western 
blot data not shown), these results suggest that lipoproteins inhibit agr-dependent Hla 
production and associated virulence in the lungs early during S. aureus infection.  
In addition to inhibiting agr-signaling, apoB on LDL also binds lipotechoic acid 
(LTA) from S. aureus and limits LTA-induced expression of IL-6 [126]. To distinguish 
between agr-dependent and agr-independent effects of lipoprotein deficiency on 
pulmonary inflammatory cytokine production, we measured lung cytokine levels in WT 
and Pcsk9-/- mice intranasally infected with LAC or LAC∆agr. In addition to IL-1β and 
IL-6, we measured production of macrophage inflammatory protein 2 (MIP-2), a 
neutrophil chemotactic protein, which has also been shown to be driven by agr-regulated 
Hla [137]. At six hours post-infection, IL-1β and MIP-2 levels were significantly 
increased in the lungs of Pcsk9-/- mice infected with LAC, but not with LAC∆agr (Figure 
3.5A,B), consistent with impaired host control of QS in the lungs of lipoprotein deficient 
mice. In contrast, compared to WT mice, IL-6 was increased in the lungs of both LAC 
and LAC∆agr infected Pcsk9-/- mice (Figure 3.5C), further supporting a role for apoB in 
limiting LTA-induced expression of this inflammatory cytokine [126]. Therefore, these 
data demonstrate that apoB limits S. aureus-induced inflammatory cytokine production in 
the lung in both an agr-dependent and an agr-independent manner.  
 
Lipoproteins regulate agr-dependent neutrophil influx in the lung 
Appropriate recruitment of neutrophils during S. aureus infection is critical for 
bacterial clearance [138]; however, excessive neutrophil recruitment can result in severe 
injury to sensitive lung tissues (reviewed in [42, 139]). Given that MIP-2 levels were  
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Figure 3.5 - Lipoproteins limit agr-dependent and agr-independent pulmonary 
cytokine expression.  
(A) IL-1β (ANOVA p=0.0035), (B) MIP-2 (ANOVA, p<0.0001) and (C) IL-6 levels in 
clarified whole lung homogenate of WT and Pcsk9
-/- 
mice (A-C, white and gray boxes, 
respectively) at 6 hours following intranasal infection with the indicated isolate (N=8 
mice per group). Data shown are mean ± SEM. (A-B) ns, not significant; *, p≤0.05, ****, 
p≤0.0001, ANOVA with Dunnett’s multiple comparison analysis. (C) *, p≤0.05, Student’s 
t-test.  
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increased in the lungs of lipoprotein deficient mice infected with LAC, but not with 
LAC∆agr, we compared myeloperoxidase (MPO) levels, a surrogate marker of 
neutrophil influx, in the lungs of LAC-infected Pcsk9-/- mice versus controls. MPO levels 
were significantly higher in the lungs of lipoprotein deficient mice (Figure 3.6A), and 
this paralleled an increase in Ly6G+ cells in BALF from 4APP- versus vehicle-treated 
mice also infected with LAC (Figure 3.6B). In contrast, neutrophil influx and MPO 
levels did not differ between 4APP- and vehicle-treated mice infected with LAC∆agr 
(Figure 3.6B) or LAC∆hla (Supplemental Figure 3.2), respectively. Furthermore, 
although macrophage levels overall were increased in BALF from LAC-infected versus 
LAC∆agr-infected mice (Figure 3.6C), macrophage presence was independent of 
circulating lipoprotein levels. Together, these data indicate that lipoproteins are important 
for early host control of agr-dependent neutrophil influx during S. aureus lung infection.  
 
ApoB limits agr-dependent cytokine expression by human alveolar 
epithelial cells 
Murine MIP-2 is a functional homologue of human IL-8, and Hla strongly 
induces IL-8 release by human alveolar epithelial cells at toxin concentrations below 
those causing cell lysis [140]. To demonstrate that lipoproteins protect against early 
inflammatory cytokine production in the lung via inhibition of agr activation, rather than 
by direct effects on lung cells or sequestration of agr-regulated virulence factors [65, 126, 
141], we measured IL-8 expression by human alveolar epithelial cells exposed to sterile 
bacterial supernatant from LAC cultured in the presence versus the absence of LDL. 
Consistent with previous reports [80, 123], LDL limited accumulation of Hla in LAC  
49 
 
 
Figure 3.6 - Lipoproteins limit agr-dependent neutrophil influx. 
(A) MPO levels in whole lung homogenate of WT and Pcsk9
-/- 
at 6 hours following 
intranasal infection with the indicated isolate (N=8 mice per group). (B) Ly6G+ and (C) 
CD11c+ cells in BALF from vehicle- and 4APP-treated mice at 6 hours post-infection. 
N=6 (LAC) and 3 (LAC∆agr) mice per group. Data shown are mean ± SEM. ns, not 
significant; *, p≤0.05. **, p≤0.01, Student’s t-test.  
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culture supernatant (Figure 3.7A), and thus hemolytic activity (Figure 3.7B), whereas 
LDL incubated with sterile supernatant post-culture, and either used immediately or after 
a one hour co-incubation, did not inhibit hemolysis. Using A549 cells as a model for 
human alveolar epithelial cells, LAC supernatant induced il-8 transcription in a dose-
dependent manner (Figure 3.7C). Furthermore, compared to IL-8 release following 
exposure to LAC supernatant, IL-8 production by A549 cells was significantly reduced 
when exposed to supernatant from LAC cultured in the presence of LDL (Figure 3.7D). 
This reduction in IL-8 was not due to direct effects of LDL on the A549 cells as LDL 
incubated with cells for one hour prior to the addition of LAC supernatant did not inhibit 
IL-8 production. Also, while there was a small reduction in IL-8 levels when LDL was 
co-incubated with LAC supernatant for one hour prior to addition to the A549 cells, this 
reduction did not reach statistical significance. This suggests that the impact of LDL on 
IL-8 expression in these assays is mainly independent of sequestration of virulence 
factors or pathogen associated molecular patterns (PAMPs) within the supernatant [65, 
126, 141]. Importantly, IL-8 production did not significantly differ between cells exposed 
to supernatant from LAC cultured with LDL and supernatant from cultures of LAC∆agr 
or LAC∆hla. Therefore, these results support a mechanism whereby apoB limits S. 
aureus QS in the lung and protects the host against excessive inflammatory cytokine 
production in response to agr-regulated virulence factors.  
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Figure 3.7 - Serum lipoproteins limit agr-dependent cytokine expression by human 
alveolar epithelial cells. 
(A) Western blot analysis and (B) functional assay of Hla in 6 hour sterile supernatant 
from LAC cultured ± LDL (100 nM), LAC supernatant with LDL (100nM) added post-
culture, post-culture supernatant incubated with LDL (100nM) for 1h, or supernatant 
from LAC∆agr or LAC∆hla. Data shown are mean ± SEM. ANOVA (p<0.0001) with 
Dunnett’s multiple comparison post-hoc analysis. ****, p≤0.0001. (C) Transcription of 
il-8 relative to hprt by A549 cells following 4 hours incubation with LAC sterile 
supernatant at the indicated dilutions, and (D) IL-8 release after 4 hours exposure to 1:10 
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dilutions of the following: i) broth control, ii) supernatant from LAC cultured in the 
absence of LDL, iii) LAC cultured in the presence of LDL (100nM), iv) LAC supernatant 
with LDL added post-culture, v) post-culture supernatant incubated with LDL for 1h or 
vi) LDL incubated with cells for 1h followed by addition of post-culture supernatant. 
Data shown are mean percent (± SEM) of IL-8 production relative to the no LDL (ii) 
control. ANOVA (p<0.0001) with Bonferroni’s multiple comparison post-hoc analysis. 
ns, not significant; *, p≤0.05; ****, p≤0.0001.  
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Discussion 
 
Considerable attention has been given to the role of hyperlipidemia in 
cardiovascular disease, such that the terms dyslipidemia and hyperlipidemia are often 
used synonymously [66]. This illustrates the limited consideration given to the potential 
health consequences of the other dyslipidemia, severe hypolipidemia and lipoprotein 
deficiency, often experienced post-trauma and by other critically ill patients [112-114]. 
Since hypolipidemia has been clinically associated with bacterial pneumonia [88-90], we 
sought to determine the impact of extremely low circulating lipoprotein levels on host 
innate defense in the lung. Using a sub-lethal mouse model of S. aureus pneumonia, we 
demonstrate that lipoprotein deficiency impairs early pulmonary innate defense against 
bacterial pathogenesis. Specifically, apoB is present in the lung early post-infection and 
its levels decrease significantly with lipoprotein deficiency. This decrease coincides with 
impaired host control of S. aureus agr-signaling, as well as increased agr-dependent 
morbidity and inflammation, in alignment with the role of apoB in controlling S. aureus 
QS-dependent virulence in the skin [80, 83, 123]. In addition, lipoprotein deficiency 
results in an agr-independent increase in pulmonary IL-6 expression, consistent with the 
ability of apoB to bind LTA and limit LTA-mediated inflammation [126]. Given that 
hyperlipidemia also impairs lung innate defense mechanisms [84], these results strongly 
suggest that maintenance of normal serum cholesterol and lipoprotein levels is necessary 
for optimal host innate defense in the lung.  
The contribution of host lipoproteins to pulmonary innate immunity is not 
surprising considering their previously described host defense contributions, together 
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with their demonstrated uptake by lung capillary endothelium [92] and carriage on 
infiltrating leukocytes [93]. For example, circulating lipoproteins, including LDL and 
high density lipoprotein (HDL), non-specifically bind and sequester LPS, thus limiting 
endotoxin induced toxicity and lethality [124, 125, 142]. In addition, apoB from LDL and 
apolipoproteins A1 and A2 from HDL bind soluble LTA and inhibit LTA-mediated 
cytokine release from both human and murine cells [126]. The most pronounced 
inhibition comes from LDL which dose-dependently inhibits LTA-mediated IL-6 
expression by human PBMCs. In support of this finding, here we show that lipoprotein 
deficiency results in significantly increased IL-6 levels in the lungs of S. aureus infected 
mice independent of agr status. Although in vivo validation of the role of lipoproteins in 
controlling LTA-mediated inflammation in the lung will require comparison of 
lipoprotein-sufficient versus -deficient mice following pulmonary administration of LTA 
or infection with LTA-deficient S. aureus mutants [143, 144], our data and that of others 
suggests that hypolipidemia may broadly impact post-trauma pneumonia susceptibility to 
both Gram positive and Gram negative pathogens. 
Along with sequestration of AIP, lipoproteins have other roles in host defense 
against S. aureus pathogenesis. Specifically, LDL has been reported to bind and partially 
inactivate Hla [141], while the phenol soluble modulins (PSMs) [122, 145, 146], which 
attract and lyse neutrophils, are also bound by lipoproteins, in particular by HDL [65]. In 
this regard, the data reported here indicate that LDL limits IL-8 production by human 
alveolar epithelial cells by inhibiting expression and secretion of agr-regulated virulence 
factors. This is supported by our findings that (i) A549 cells produce IL-8 when exposed 
to LAC sterile supernatant, but not when exposed to sterile supernatant from LAC∆agr or 
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LAC∆hla, (ii) that inclusion of LDL during LAC culture limits both Hla accumulation in 
the supernatant [80, 123] and the ability of the resulting supernatant to induce IL-8 
release by A549 cells and (iii) that the addition of LDL to directly to LAC supernatant 
does not inhibit IL-8 release by A549 cells. Although these data suggest that LDL 
primarily functions by prevention of virulence factor expression in this system, 
lipoproteins may also directly inhibit virulence factor function in the lung. Here, 
pulmonary administration of LAC supernatant, purified Hla or PSMs to serum 
lipoprotein-sufficient versus -deficient mice would further clarify this issue. Regardless, 
our findings and those of others [65, 66, 84, 124-126, 141] strongly suggest that 
lipoproteins likely contribute in a variety of both direct and indirect means to pulmonary 
host innate defense.  
In addition to the negative effects of lipoprotein deficiency on pulmonary innate 
immunity reported here, severe hypolipidemia may also impair the innate defense 
function of lung surfactant (reviewed in [86]). Lung surfactant is comprised of a mixture 
of lipids, phospholipids and proteins, and maintenance of the appropriate ratios of these 
components is required for functional surfactant self-assembly [85, 147, 148]. Of 
particular importance to surfactant-mediated host innate defense are the surfactant-
associated proteins, SP-A and SP-D, which act as opsonins to promote bacterial clearance 
[149-153]. Since lipoproteins contribute to the regulation of surfactant cholesterol 
metabolism [154], it is unclear whether severe hypolipidemia results in impaired 
surfactant assembly and negatively impacts bacterial clearance by altering the distribution 
or otherwise impairing the antibacterial functions of SP-A and SP-D. While we saw no 
evidence of impaired pulmonary bacterial clearance in lipoprotein deficient mice at the 
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early post-infection time point investigated here, the potential impact of severe 
hypolipidemia on pulmonary bacterial clearance warrants further investigation.  
By focusing on early control of S. aureus QS in the lung, we have demonstrated 
one mechanism by which severe hypolipidemia impairs pulmonary host innate defense. 
Although a significant gap in knowledge remains regarding the full impact of 
hypolipidemia on infection susceptibility, disease progression and survival during 
pneumonia caused by S. aureus and other microbial pathogens, the work reported here 
regarding hypolipidemia, together with the work of others focused on hyperlipidemia 
[84], represent important advances in understanding the impact of both extremes of 
dyslipidemia on pulmonary host innate defense. Furthermore, these studies point to the 
potential clinical impact of severe hypolipidemia on pulmonary innate defense in 
critically ill patients. 
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Supplemental Information 
 
 
Supplimental Figure 3.8 - agr-regulated transcription is increased in LAC collected 
by BAL from lipoprotein deficient mice. 
Bacteria in BALF was collected at six hours following intranasal infection of vehicle- or 
4APP-treated mice. Relative quantification (RQ) of RNAIII and lukS-PV  transcription 
relative to 16S was determined by qRT-PCR. Data shown as mean ± SEM. N= 8 mice per 
group. *, p≤0.05; **, p≤0.01, Student’s t-test.  
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Supplimental Figure 3.9 - Percent weight loss is increased in LAC infected 
lipoprotein deficient mice. 
Vehicle- or 4APP-treated (left) and B6 x 129 (WT) or Pcsk9-/- mice (right) were 
intranasally infected with agr::P3-YFP LAC (4 x 108 CFU). Mice were weighed at the 
time of infection and at 6 hours post-infection. Data shown as median and 5th-95th 
percentile. N= 7-8 mice per group. *, p≤0.05; **, p≤0.01, Mann-Whitney test.  
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Supplimental Figure 3.10 - MPO levels in lung homogenate from LAC∆hla infected 
mice. 
MPO in whole lung homogenate of vehicle- and 4APP-treated mice at 6 hours following 
intranasal infection with LAC∆hla. Data shown as mean ± SEM. N= 12 mice per group. 
ns, not significant, Student’s t-test.  
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Chapter 4 – Discussion 
 
There is a growing body of evidence in the literature for lipoprotein particles as 
contributors to host innate immunity against a multitude of pathogens [55-66] (Table 1). 
However, aside from data presented in Chapter 3, there is no direct evidence showing 
how hypolipidemia affects pulmonary innate immunity. Investigation of the contributions 
of lipoproteins to pulmonary innate immunity presents a unique opportunity to 
understand the potentially complicated interplay of lipoproteins, the immune system, and 
related host-pathogen interactions.  
Given that most research on the consequences of dyslipidemia has been largely 
focused on hyperlipidemia, due to its impact on cardiovascular disease [46-49], there is a 
critical gap in knowledge as to what role hypolipidemia may play in pulmonary host 
innate immune defense. The potential negative effects and associations of hypolipidemia 
include impacts on plasma membrane composition and fluidity, increased risk of cerebral 
hemorrhage, adrenal failure, and mortality during sepsis and other critically ill states, 
such as extreme trauma or pneumonia [155-161]. In Chapter 3, we presented evidence 
that very low apoB containing serum lipoprotein levels during S. aureus pneumonia leads 
to increased QS, resulting in increased inflammation and neutrophil recruitment to the 
lung at early time points of infection (Figure 4.1). To our knowledge, this is the first 
indication that reduced serum lipoproteins impair innate immune defense during 
pulmonary infection.  
Despite the growing body of evidence that lipoproteins play an important role in 
innate immunity, there are still many gaps in knowledge to address, including i) what are
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Figure 4.1 – ApoB in pulmonary defense against S. aureus. 
Lowered apoB-containing serum lipoprotein levels during S. aureus pneumonia leads to 
increased QS, resulting in increased inflammation and neutrophil recruitment to the lung 
at early time points of infection. 
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effects of hypolipidemia on lung surfactant structure and function in innate immunity? ii) 
what are the effects of hypolipidemia directly on pulmonary immune cells and 
inflammation? and iii) how do cholesterol lowering dependent and independent effects of 
drugs, such as statins, contribute to pulmonary infection outcomes? Herein we address 
these gaps in knowledge based on the available literature, as well as discuss how 
hypolipidemia may affect infection with other lung pathogens, some of the pros and cons 
of hyper- and hypolipidemia in infection and immunity, and highlight the concept that 
either extreme of dyslipidemia can have negative consequences in pulmonary infection 
and immunity. 
  
i) Serum lipoprotein and pulmonary surfactant structure and function 
 
Pulmonary surfactants are primarily composed of lipids and cholesterol and 
function to lower surface tension at the air-to-surface interface in the lung, as well as help 
serve as a physical barrier for removal of particulates from the lung [162].  Abnormal 
levels of cholesterol carrying serum lipoproteins, high or low, have been shown to have 
detrimental impacts on pulmonary surfactant structure and ability to function as a surface 
tension regulator in the lung [85, 147], consistent with evidence that dyslipidemia in 
either direction has negative health effects. The effects of lipoproteins on surfactant 
composition, structure and function, as well anti-microbial surfactant proteins, merits 
further investigation. 
The antimicrobial surfactant proteins SP-A and SP-D interact with a wide variety 
of pathogens, including S. aureus, S. pneumoniae, and group A Streptococcus [163-167], 
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bind LPS [168], and opsonize bacteria for phagocytosis by alveolar macrophages (AM) 
[152]. Interestingly, serum proteins can inhibit surfactant surface tension lowering 
activity [169, 170], and SP-A reduces this inhibition  [171], suggesting a potential role 
for serum proteins in regulating normal lung function during infection. Hypolipidemic 
states may contribute to dysregulation of the interplay of lung specific factors, such as 
SP-A and SP-D, leading to worse clinical outcomes in patient populations that are more 
susceptible to pulmonary infection with a multitude of pathogens.  
Despite this, the effects of hypolipidemia on SP-A and SP-D function and 
potential consequences for how it might affect gene regulation or protein expression 
during pulmonary infection, has not been investigated. Given that we know lipoproteins 
can have detrimental effects on lung surfactants, and that serum lipoprotein levels effect 
lipoprotein levels in the lung, we hypothesize that SP-A and SP-D function and 
regulation may be affected by serum lipoprotein levels, leading to different outcomes 
during pulmonary infection in an in vivo model. Include collected lung samples for qRT-
PCR of SP-A/SP-D To test this, we would first consider the effects of the addition of 
serum lipoproteins on SP-A and SP-D expression and secretion from A549 cells 
[172].Additionally, regulation of SP-A and SP-D in our hypolipidemic mouse models 
(detailed in Chapter 3), compared to controls would represent an important next 
evaluation. The results of these experiments could have further implications in the 
contributions of serum lipoproteins in pulmonary innate immunity against a variety of 
pathogens. 
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ii) Serum lipoproteins modulate the inflammatory response 
 
In addition to the potential effects of lipoproteins on physical immune barriers 
such as surfactant and associated surfactant proteins, we know from studies of 
atherosclerosis that serum lipoproteins can also modulate inflammatory responses in 
many different cell types [173]. For example, exposure of macrophages to modified LDL 
increases expression of the oxidized LDL (oxLDL) scavenger receptor, CD36, which 
contributes to development of foam cells in auto-immune development of atherosclerotic 
lesions [174]. OxLDL can also induce monocyte chemoattractant protein-1 (MCP-1) 
expression from endothelial cells, inhibit macrophage migration, and induce 
proinflammatory cytokine expression from macrophages [173]. SP-A has also been 
shown to induce respiratory burst and nitric oxide synthase (NOS) expression in AMs 
[32]. Furthermore, uptake of LDL by the LDLR on neutrophils transiently increases their 
oxidative burst [175], which is important in auto-immune development of atherosclerosis 
via oxidative modification of LDL, as well as important in microbial killing. 
Unsurprisingly, systemic oxidation of lipoproteins occurs during the acute phase response 
to LPS induced septic shock [176]. Myeloperoxidase (MPO) produced by neutrophils 
during infection is important in oxidative killing of microbes via production of cell 
generated hypochlorous acid, which can also oxidize lipoproteins [177]. Additionally, 
HDL has also been shown to mediate anti-inflammatory reprogramming of macrophages 
through reduced expression of TLR-induced cytokines [178], to attenuate neutrophil 
activation via reduction of lipid raft abundance associated with CD11b activation [179], 
and limit the oxidative burst of neutrophils by oxLDL [180]. Based on these studies, it is 
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clear that lipoproteins play an important role in helping activate inflammatory responses, 
are modified by ROS produced by activated leukocytes, and that these modified 
lipoproteins can further modulate inflammation. However, since most atherosclerosis 
research is done in hyperlipidemic models, there is a need to address how extreme 
hypolipidemia may affect innate immune cell signaling and function, particularly in the 
context of pulmonary infection. 
Despite the wealth of research on lipoproteins in atherosclerosis, there is 
conflicting literature regarding the effects lipoproteins and cholesterol can have both 
detrimental and beneficial immunomodulatory and inflammatory effects during 
infections. For example, exposure of guinea pigs to Mycobacterium tuberculosis 
increases expression of CD36 on AMs, thus increasing uptake of oxLDL by AMs 
resulting in increased intracellular bacterial survival [181], likely due to use of 
cholesterol as a carbon source by M. tuberculosis. Additionally, deletion of the ATP-
binding cassette transporter A1 (ABCA1), which plays a role in efflux of intracellular 
free cholesterol, has been shown to increase resistance to infection via increases in the 
proinflammatory state of macrophages, in a mouse model of intraperitoneal Listeria 
monocytogenes [182]. The deletion of ABCA1 also resulted in higher systemic 
concentrations of MCP-1, MIP-2, and IL-6. Given our findings showing association of 
elevated MIP-2 and neutrophil recruitment with worse disease outcomes in the lung in 
lipoprotein deficient mice, one may expect that a mutation which causes dysfunction in 
ABCA1, and the associated lipid metabolism differences could have different effects in a 
pulmonary disease model. Interestingly, cholesterol crystals have been shown to prime 
neutrophils to release neutrophil extracellular traps (NETs), prime macrophages to 
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release IL-1β, and activate T helper 17 cells which increase immune cell recruitment 
[183]. It has also been hypothesized that oxidation-specific epitopes on oxLDL that are 
similar to epitopes on pathogens, serve to maintain natural antibodies against those 
pathogens [184]. Together, these varied studies indicate the complex interplay of 
lipoproteins and the immune system and the importance of both extremes of dyslipidemia 
to negative disease states or infection outcomes. Given this, and the increased presence of 
serum lipoproteins in the lung during infection, a role for lipoproteins in directly 
modulating inflammation during pulmonary infection may be indicated. 
 
iii) Statins in innate immunity and pleotropic effects on inflammation 
 
 Statins as treatments for lowering cholesterol can dramatically reduce instances of 
cardiovascular disease [185, 186]. In contrast to the idea that severe reduction in 
cholesterol levels could knockdown serum lipoproteins as an innate immune barrier [87], 
statins appear to have some beneficial effects in severe infectious disease outcomes. For 
example, in a clinical study of 575 patients, looking at pre-hospitalization use of statins, 
beneficial effects were found in lowering rates of sepsis and pneumonia in humans during 
early critical illness [187]. A conflicting clinical study’s results showed no benefits to 90-
day mortality rates in community acquired pneumonia (CAP) patients, and no significant 
elevation in plasma markers of severe sepsis and CAP, such as inflammatory cytokines 
and leukocyte cell surface protein expression markers [188]. However, the authors of this 
study still suggest that the trends favored statin usage over no statin usage, and suggest 
(while not statistically significant) a potentially clinically meaningful benefit of statin 
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usage in CAP cases. While prophylactic usage of statins appeared to have beneficial 
effects in these severe disease outcomes, post-hospitalization treatment with statins 
appeared to have no effect in either study [187, 188].   
The suggestion that statins have a clinically beneficial role in severe disease 
outcomes merits further investigation into the mechanisms behind this benefit. 
Laboratory investigations  found that simvastatin may play a role in inhibiting the actin 
dynamics in human endothelial cells required for S. aureus endocytosis and invasion 
[189], inhibit LTA induced inflammation in human AMs through inhibition of NF-κB 
activation [190], and enhance extracellular trap formation by human and murine 
leukocytes via inhibition of sterol production [191]. Another study found that simvastatin 
and pravastatin (at sub-cholesterol lowering concentrations) were able to limit the 
cytotoxicity of Hla and pneumolysin, a major pore forming toxin of S. pneumoniae , 
against human airway epithelial cells [192], and that the mechanism for this was 
independent of the cholesterol-lowering mevalonate pathways. These studies indicate that 
statins have a pleotropic role in lowering damaging inflammatory responses via 
mechanisms independent of their targeted use against cardiovascular disease. This further 
indicates the complicated and sometimes paradoxical interplay of the pulmonary immune 
milieu in clearing infection, through phagocytosis and killing of bacterial pathogens, 
while simultaneously limiting potentially damaging inflammation. These findings present 
interesting avenues for research looking at these effected pathways for lowering initial 
inflammatory responses in severe infection cases.  
Despite evidence suggesting that statin usage may be beneficial in severe sepsis 
and pulmonary disease outcomes, there are no reports looking at statin usage and the state 
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of hypolipidemia during severe pulmonary infection. The evidence showing sub-
cholesterol lowering, anti-inflammatory effects of statins may indicate confounding 
variables in statin using patients in extreme hypolipidemic states and merits further 
investigation. We propose that sub-cholesterol lowering concentrations of statins could 
have beneficial immunomodulatory effects on inflammatory signaling, and detrimental 
effects during infection at higher concentrations (relevant to CVD treatment) via further 
knockdown of lipoproteins as innate immune barriers. Given the wide usage of statins, 
perhaps this could be elucidated by doing a database search of clinical outcomes in 
hypolipidemic patient populations (such as in the case of severe trauma), comparing 
statin and non-statin users. We would also suggest experiments to test the effects of 
simvastatin treatment at previously reported sub-cholesterol reduction levels (10 nM to 
1000 nM) [192] in a lipoprotein deficient mouse model of S. aureus pulmonary infection, 
compared to control mice. We would predict that pre-infection statin treatment would 
have beneficial effects in control mice at sub-cholesterol reducing levels, but increase QS 
and resulting inflammation and disease in lipoprotein deficient mice. The results of these 
studies could point to sub-cholesterol reducing levels of statins as potential treatments in 
critically ill patient populations. 
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Closing comments  
 
Lipoprotein research has been primarily focused in the area of hyperlipidemia, 
largely because of its known association with increased CVD and atherosclerosis. 
Through this, the scientific community’s understanding of lipoproteins as immune system 
modulators and causes of immune dysfunction in these disease states, is vast. Perhaps 
naturally arising from this large body of research is more recent research showing that 
hyperlipidemia has important consequences in infectious disease outcomes 
(Madenspacher et al., 2010, From Paper), and that infectious agents can also enhance 
disease progression in CVD and atherosclerosis (Dutta et al. 2009, Repeated Systemic). 
However, there is comparatively very little research on the effects of hypolipidemic states 
and their contributions to infectious disease.  
Given the importance of CVD and atherosclerosis, statins have become some of 
the most prescribed drugs world-wide (Herbert et al. 1997, Cholesterol Lowering, Gotto 
1997, Cholesterol Management). However, because of the limited research done on the 
effects of hypolipidemia during trauma and outcomes in infectious disease, the 
consequences of statins as reducers of lipoproteins as an innate immune barrier in these 
populations has not been accurately assessed. Furthermore, whether the potentially 
beneficial effects of statins that are unrelated to their ability to lower cholesterol are 
outweighed by further knockdown of lipoproteins as agents of innate immunity has not 
been thoroughly investigated in hypolipidemic patient populations. 
One of the hallmarks of susceptibility to infection is a compromised immune 
system.  Perhaps not coincidentally, individuals recovering from traumatic insult are 
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likely to have lowered serum levels of circulating apoB containing lipoproteins, and are 
more susceptible to infection [91]. Addressing the gaps in knowledge described above 
may have implications in early prediction of pneumonia susceptibility in trauma patients.  
Perhaps lipoproteins as potential future treatment options could ultimately help contribute 
to better outcomes in hypolipidemic patients who are more susceptible to infection. 
Additionally, the studies discussed herein suggest that lipoproteins could serve as an 
innate immune barrier during early infection in the lung against a multitude of pathogens. 
The lung is particularly sensitive to damage caused by infectious disease and 
inflammation. Due to the lungs indispensability as an organ, pneumonia in particular is 
an important and severe disease state, resulting in overall high levels of morbidity and 
mortality. Though the lung has become highly adapted with physical barriers, and unique 
antimicrobial agents and resident immune cells, likely because of these very reasons, it 
also presents a unique disease microenvironment where lipoproteins may have even 
further pleotropic effects beyond direct innate immune agents and inflammatory signaling 
modulators. Based on the presented research, as well as our own findings, dyslipidemia in 
either direction appears to have detrimental effects in infectious disease outcomes in 
pulmonary infection. Both over activation of inflammatory signaling and lack of infection 
control may be particularly detrimental in the lung, with over activation of inflammatory 
signaling leading to increased inflammation induced damage. Perhaps when dyslipidemia 
in either direction can cause dysregulation of inflammatory signaling, or deficiencies in 
innate immunity and ultimately lack of pathogen control, leading to increased toxin 
induced inflammation and tissue damage.  
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Appendix A: Abbreviations 
 
4APP    4-aminopyrizolo[3,4-d]pyrimidine 
agr    Accessory gene regulator 
AIP    Auto-inducing peptide 
AM    Alveolar macrophage 
AMP    Antimicrobial peptide 
ApoA1   Apolipoprotein A1 
ApoA2   Apolipoprotein A2 
ApoB    Apolipoprotein B 
ApoB-48   N-terminal 48% of apolipoprotein B 
ApoC1   Apolipoprotein C1 
ApoC2   Apolipoprotein C2 
ApoE    Apolipoprotein E 
APR    Acute phase response 
BALF   Bronchial alveolar lavage fluid 
BCIP    5-bromo-4-chloro-3-indolyl-phosphate  
BSA    Bovine serum albumin 
CA-MRSA   Community acquired methicillin-resistant Staphylococcus aureus 
CAP    Community acquired pneumonia 
CDC  Centers for Disease Control 
cDNA   Complimentary deoxyribonucleic acid 
CFU    Colony forming unit 
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CVD    Cardiovascular disease 
DC    Dendritic cell 
HAP    Hospital acquired pneumonia 
HDL    High density lipoprotein 
Hla    Alpha-hemolysin 
hLDL    Human low density lipoprotein 
i.n.    Intranasal 
LDL    Low density lipoprotein 
LDLR   Low density lipoprotein receptor 
LPS    Lipopolysaccharide 
LTA    Lipoteichoic acid 
mAb    Mouse antibody 
MCF    Mean channel fluorescence 
MPO    myeloperoxidase 
MRSA   Methicillin-resistant Staphylococcus aureus 
NBT    Nitroblue tetrazolium 
NET    Neutrophil extracellular trap 
NK    Natural killer cell 
NOS    Nitric oxide synthase 
ns    Not significant 
oxLDL   Oxidized low density lipoprotein 
PAGE   Polyacrylamide gel electrophoresis 
PAMP   Pathogen-associated molecular pattern 
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PBMC   Peripheral blood mononuclear cell 
PBS    Phosphate buffered saline 
PSM    Phenol soluble modulins 
PVDF   Polyvinylidene fluoride 
PVL    Panton-Valentine leucocidin 
qRT-PCR   Quantitative real-time polymerase chain reaction 
QS    Quorum sensing 
RBC    Red blood cell 
RNA    Ribonucleic acid 
RNS    Reactive nitrogen species 
ROS    Reactive oxygen species 
RQ    Relative quantification 
RT    Reverse transcriptase 
SEM    Standard error of the mean 
SSSI    Skin and skin structure infection 
TBS    Tris buffered saline 
TLR    Toll-like receptor 
TSB    Tryptic Soy Broth 
VLDL   Very low density lipoprotein 
WT    Wild-type 
YFP    Yellow fluorescent protein 
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